Prime Medicine Secures $144.2 Million in Public Offering
Deal News | Aug 07, 2025 | Goodwin
Prime Medicine, a pioneering biotechnology company, has successfully raised $144.2 million through an underwritten public offering of 43.7 million shares of its common stock, priced at $3.30 per share. This sum includes shares acquired through the full exercise of the underwriters’ option to purchase 5.7 million additional shares. Notably, the underwriters received no discounts or commissions for an aggregate of 1,818,181 shares sold to the Cystic Fibrosis Foundation. The offering was facilitated by the advisory services of the Goodwin Life Sciences team, spearheaded by key figures including Kingsley Taft and others across specialties like FDA regulations and intellectual property. Prime Medicine uses its proprietary Prime Editing platform to advance gene editing therapies, aiming to deliver precise, one-time curative treatments by minimizing DNA alterations. Goodwin's involvement underscores the collaborative effort of various legal and scientific expertise to support Prime Medicine's innovative endeavors.
Sectors
- Biotechnology
- Life Sciences
- Healthcare
Geography
- United States – Prime Medicine and Goodwin are based in the United States, indicating the geographic focus of the business operation and legal jurisdiction.
Industry
- Biotechnology – The article focuses on Prime Medicine, a company within the biotech sector, particularly in gene editing technology.
- Life Sciences – Relevant due to the role of Goodwin's Life Sciences team advising on the public offering and the nature of Prime Medicine's business.
- Healthcare – Prime Medicine is engaged in advancing healthcare solutions through its gene editing technology, a crucial development in medical sciences.
Financials
- $144.2 million – Gross proceeds raised by Prime Medicine from the public offering.
- 43,700,000 – Total number of shares sold in the public offering.
- $3.30 – Price per share in the public offering.
Participants
| Name | Role | Type | Description |
|---|---|---|---|
| Prime Medicine | Target company | Company | A biotechnology firm focused on gene editing therapies using its proprietary Prime Editing platform. |
| Goodwin | Legal advisor | Company | The law firm advising Prime Medicine on its public offering, providing expertise across various legal disciplines. |
| Cystic Fibrosis Foundation | Buyer of shares | Charity | An organization purchasing shares without underwriter discounts, indicating involvement in potential philanthropic or investment activities. |